Drug Eluting Stent News and Research

RSS
A drug-eluting stent (DES) is a coronary stent (a scaffold) placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. This prevents fibrosis that, together with clots (thrombus), could otherwise block the stented artery, a process called restenosis.
Extended P2Y12 inhibitor monotherapy reduces bleeding and ischemic events in ACS patients

Extended P2Y12 inhibitor monotherapy reduces bleeding and ischemic events in ACS patients

OCT-guided PCI does not reduce target vessel failure in complex patients, but improves safety

OCT-guided PCI does not reduce target vessel failure in complex patients, but improves safety

Dual-antiplatelet therapy should remain the standard strategy for PCI even in the drug-eluting stent era

Dual-antiplatelet therapy should remain the standard strategy for PCI even in the drug-eluting stent era

Bioresorbable vascular scaffolds may be just as effective as drug-eluting metal stents for treating heart disease patients

Bioresorbable vascular scaffolds may be just as effective as drug-eluting metal stents for treating heart disease patients

Research investigates how drug-eluting stent affects arterial tissue permeability and blood flow

Research investigates how drug-eluting stent affects arterial tissue permeability and blood flow

New exosome-coated stent repairs damaged tissue, heals vascular injury

New exosome-coated stent repairs damaged tissue, heals vascular injury

Study highlights the role of genetic testing in evaluation of in-stent thrombosis

Study highlights the role of genetic testing in evaluation of in-stent thrombosis

Short, one-month dual anti-platelet treatment is safe and effective after stent placement

Short, one-month dual anti-platelet treatment is safe and effective after stent placement

Study shows best antiplatelet treatment after transcatheter aortic valve implantation

Study shows best antiplatelet treatment after transcatheter aortic valve implantation

TWILIGHT trial: Brilinta reduces bleeding compared to dual therapy in high-risk coronary patients

TWILIGHT trial: Brilinta reduces bleeding compared to dual therapy in high-risk coronary patients

Polymer drug-eluting and polymer-free drug-coated stents safe and effective for patients with high bleeding risk

Polymer drug-eluting and polymer-free drug-coated stents safe and effective for patients with high bleeding risk

Ticagrelor monotherapy reduces bleeding while preserving ischemic benefit in high-risk PCI patients

Ticagrelor monotherapy reduces bleeding while preserving ischemic benefit in high-risk PCI patients

Shorter duration DAPT after PCI did not increase adverse events in high-bleeding risk patients, finds study

Shorter duration DAPT after PCI did not increase adverse events in high-bleeding risk patients, finds study

High-risk heart patients may not require long-term aspirin use after stent placement

High-risk heart patients may not require long-term aspirin use after stent placement

ACC Asia Conference 2019 brings experts to discuss latest cardiovascular science

ACC Asia Conference 2019 brings experts to discuss latest cardiovascular science

Study indicates the benefits of stopping aspirin in heart attack patients

Study indicates the benefits of stopping aspirin in heart attack patients

FDA approves new 5 mm diameter drug-eluting stent from Cook Medical

FDA approves new 5 mm diameter drug-eluting stent from Cook Medical

Clinical study shows efficacy, safety of novel drug-eluting stent with improved radiographic visibility

Clinical study shows efficacy, safety of novel drug-eluting stent with improved radiographic visibility

Drug coated balloons are as good as stent implants for treating small blocked arteries

Drug coated balloons are as good as stent implants for treating small blocked arteries

Antiplatelet monotherapy appears to be safer but does not reduce risk of heart attack

Antiplatelet monotherapy appears to be safer but does not reduce risk of heart attack